Epigenomics AG (ECX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Epigenomics AG (ECX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10104
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Epigenomics AG (Epigenomics) is a molecular diagnostics company which develops and commercializes in-vitro diagnostic (IVD) tests for screening, early detection and diagnosis of cancer. Its lead product, Epi proColon is a blood-based test for rapid detection of colorectal cancer; and Epi proLung, a validating test for the diagnosis of lung cancer. The company’s molecular diagnostic products are based on its proprietary methylation technology, which is based on biological phenomenon called DNA methylation. Epigenomics’ pipeline also comprises tests for monitoring, screening, diagnosis and prognosis assessment of colorectal and lung cancer. It also offers services such as basic research, product development, validate DNA methylation (epigenetic) biomarkers and support for obtaining regulatory approvals. Epigenomics is headquartered in Berlin, Germany.

Epigenomics AG (ECX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Epigenomics AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Epigenomics AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Epigenomics AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Epigenomics AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Epigenomics AG, Medical Devices Deals, 2012 to YTD 2018 9
Epigenomics AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Epigenomics AG, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Epigenomics And Wuhan Kindstar Enter Into Licensing Agreement For Epi Prolung 11
Equity Offering 12
Epigenomics Raises USD25.71 Million in Rights Offering of Shares 12
Epigenomics Files Draft Registration Statement for US Public Offering of Shares 14
Debt Offering 15
Epigenomics Raises USD8.5 Million in Private Placement of Bonds 15
Epigenomics AG – Key Competitors 16
Epigenomics AG – Key Employees 17
Epigenomics AG – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Financial Announcements 19
Aug 08, 2018: Epigenomics Announces 2018 Second Quarter and Six Month Financial Results 19
May 09, 2018: Epigenomics announces 2018 First Quarter Financial Results 20
Mar 23, 2018: Epigenomics Reports Results for Financial Year 2017 21
Nov 15, 2017: Epigenomics Announces 2017 Third Quarter and Nine Months Financial Results 23
Aug 09, 2017: Epigenomics Announces 2017 Second Quarter and Six Months Financial Results 24
Corporate Communications 25
Nov 29, 2017: Supervisory Board of Epigenomics AG Appoints Albert Weber as Executive VP Finance and a Member of the Management Board (Vorstand) 25
Nov 05, 2017: Supervisory Board of Epigenomics Appoints Dr. Jorge Garces as President and Chief Scientific Officer 26
Other Significant Developments 27
Jul 25, 2018: Launch of Single Cell Accelerator drives VIB to forefront of single cell research 27
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Epigenomics AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Epigenomics AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Epigenomics AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Epigenomics AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Epigenomics AG, Deals By Therapy Area, 2012 to YTD 2018 8
Epigenomics AG, Medical Devices Deals, 2012 to YTD 2018 9
Epigenomics AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Epigenomics And Wuhan Kindstar Enter Into Licensing Agreement For Epi Prolung 11
Epigenomics Raises USD25.71 Million in Rights Offering of Shares 12
Epigenomics Files Draft Registration Statement for US Public Offering of Shares 14
Epigenomics Raises USD8.5 Million in Private Placement of Bonds 15
Epigenomics AG, Key Competitors 16
Epigenomics AG, Key Employees 17
Epigenomics AG, Subsidiaries 18

List of Figures
Epigenomics AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Epigenomics AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Epigenomics AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Epigenomics AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Epigenomics AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Epigenomics AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Epigenomics AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Epigenomics AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Epigenomics AG, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Epigenomics AG (ECX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Wake Forest Innovations:製薬・医療:M&Aディール及び事業提携情報
    Summary Wake Forest Innovations (Wake Forest), a subsidiary of Wake Forest Baptist Medical Center, is a health care service provider. The center offers development and commercialization of discoveries; services; and products such as medicines and vaccines, from the Medical Center and Wake Forest Uni …
  • Fate Therapeutics Inc (FATE):製薬・医療:M&Aディール及び事業提携情報
    Summary Fate Therapeutics Inc (Fate Therapeutics) is a biopharmaceutical company that develops programmed cellular therapies for cancer and immune disorders. The company’s pipeline product candidates include cellular immunotherapy pipeline, immuno-oncology candidates, and immuno-regulatory candidate …
  • HealthTronics Inc:医療機器:M&Aディール及び事業提携情報
    Summary HealthTronics Inc (HealthTronics), a subsidiary of Altaris Capital Partners, LLC, carries out manufacturing, marketing and distribution of lithotripters, cryoblation devices and nerve monitoring equipment. The various products and services offered by the company include lithotripsy services, …
  • ABM Industries Incorporated (ABM):企業の財務・戦略的SWOT分析
    ABM Industries Incorporated (ABM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Sorrento Therapeutics, Inc.:企業のM&A・事業提携・投資動向
    Sorrento Therapeutics, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sorrento Therapeutics, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Korea Western Power Co Ltd-エネルギー分野:企業M&A・提携分析
    Summary Korea Western Power Co., Ltd. (KOWEPO), a subsidiary of Korea Electric Power Corporation (KEPCO), develops electricity resources, and generates and supplies electricity. The company’s power generation portfolio includes Taen, Pyeongtaek, Seoincheon, and Gunsan power complexes consisting of t …
  • Rexnord Corp (RXN):企業の財務・戦略的SWOT分析
    Rexnord Corp (RXN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Reach Subsea ASA (REACH):企業の財務・戦略的SWOT分析
    Reach Subsea ASA (REACH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Orpea SA (ORP):企業の財務・戦略的SWOT分析
    Summary Orpea SA (Orpea) is a healthcare consulting company that offers clinical care services. The company provides services such as suite care clinic services, retirement homes, and mental hospital services, among others. Its mental hospital services include treatment of mood disorders, overuse sy …
  • Haseko Corporation:企業の戦略・SWOT・財務情報
    Haseko Corporation - Strategy, SWOT and Corporate Finance Report Summary Haseko Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Adamis Pharmaceuticals Corp (ADMP):企業の財務・戦略的SWOT分析
    Summary Adamis Pharmaceuticals Corp (Adamis), formerly Cellegy Pharmaceuticals Inc, is a biopharmaceutical company that develops therapies in areas of respiratory disease and allergy. The company offers pipeline product, epinephrine pre-filled syringe is developed for anaphylactic reactions such as …
  • ECO Animal Health Group Plc (EAH):企業の財務・戦略的SWOT分析
    Summary ECO Animal Health Group Plc (ECO) is a veterinary products manufacturer that offers therapeutic products. The company develops, registers and markets pharmaceutical products and chemicals for animal health markets. ECO produces proprietary patented drugs that are used for the treatment of re …
  • Onex Corporation (ONEX):企業の財務・戦略的SWOT分析
    Onex Corporation (ONEX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Accelerate Resources Ltd (AX8):企業の財務・戦略的SWOT分析
    Accelerate Resources Ltd (AX8) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • ContraVir Pharmaceuticals Inc (CTRV)-製薬・医療分野:企業M&A・提携分析
    Summary ContraVir Pharmaceuticals Inc (ContraVir) is a biopharmaceutical company that focusses on development and commercialization of targeted antiviral therapies. The company’s pipeline product includes TXL, potent prodrug of antiviral tenofovir and CRV431 cyclophilin inhibitor that increases its …
  • Lakeland Financial Corporation:企業の戦略・SWOT・財務情報
    Lakeland Financial Corporation - Strategy, SWOT and Corporate Finance Report Summary Lakeland Financial Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Ardelyx Inc (ARDX):企業の財務・戦略的SWOT分析
    Summary Ardelyx Inc (Ardelyx) is a developer of small molecule therapeutics for treatment of cardio-renal, gastrointestinal and metabolic disorders. The company offers products such as tenapanor, and RDX013. Its products are used for hyperphosphatemia in patients with end-stage renal disease; consti …
  • DHI Group Inc:企業のM&A・事業提携・投資動向
    DHI Group Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's DHI Group Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • BFS Group Limited:企業の戦略・SWOT・財務情報
    BFS Group Limited - Strategy, SWOT and Corporate Finance Report Summary BFS Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Oxurion NV (OXUR):企業の財務・戦略的SWOT分析
    Oxurion NV (OXUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆